Roche Expands Point of Care Diagnostics Portfolio with $295M Acquisition of LumiraDx's Point of Care Diagnostics Platform

Basel, December 29, 2023 (Reuters) -- The Swiss pharmaceutical company, announced its agreement to acquire LumiraDx's (LMDX.O) Point of Care diagnostics platform business which offers a variety of immunoassay and clinical chemistry tests on a single platform, for approximately $295 million. The completion of the transaction is anticipated by mid-2024, at which point the acquired business segment will be integrated into Roche's diagnostics unit, as stated by the pharmaceutical company.

Read full article here.